🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆
Updated 06 Sep 2026 · ClinicalTrials.gov

Clinical Trials in the UK

The most recently updated industry-sponsored clinical trials recruiting across the United Kingdom — searchable by condition, sponsor, phase and city. Refreshed daily from the ClinicalTrials.gov registry.

117
Recruiting now
160
Studies tracked
139
Cities with sites
Recruiting Phase 3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · started 2023-08-28
Ilford · Swinton · London · Aberdeen · Chertsey
NCT06126224 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Obesity, Weight Gain
Eli Lilly and Company · started 2024-06-03
Cambridge · Glagow · Leeds · Leicester · Liverpool
NCT06439277 on ClinicalTrials.gov ↗
Recruiting
Post-Market Clinical Follow-up (PMCF) Study of the Pitch-Patch for the Augmentation or Reinforcement of the Rotator Cuff
Rotator Cuff Tear, Rotator Cuff Tears, Rotator Cuff Tears of the Shoulder, Rotator Cuff Injuries
Xiros Ltd · started 2026-06-16
Reading
NCT05906004 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
Hemophilia A
Hoffmann-La Roche · started 2026-04-27
London · Cardiff
NCT07416604 on ClinicalTrials.gov ↗
Active Phase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals · started 2023-03-09
Luton · High Wycombe · Peterborough · Connor Downs · Fowey
NCT05739383 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Non-small Cell Lung Cancer
BioNTech SE · started 2025-01-07
Bath · Brighton · Cardiff · Chelsea · Cottingham
NCT06712316 on ClinicalTrials.gov ↗
Recruiting Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
Hypereosinophilic Syndrome
GlaxoSmithKline · started 2022-09-06
Leicester
NCT05334368 on ClinicalTrials.gov ↗
Active Phase 2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Solid Tumors
Hoffmann-La Roche · started 2021-01-18
Glasgow · London · Manchester
NCT04589845 on ClinicalTrials.gov ↗
Active Phase 3
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
Follicular Lymphoma, Marginal Zone Lymphoma
Incyte Corporation · started 2021-04-15
Birmingham · Bristol · Leicester · London · Manchester
NCT04680052 on ClinicalTrials.gov ↗
Recruiting Phase 4
A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies
Breast Cancer
Hoffmann-La Roche · started 2024-04-02
Basingstoke · London · Manchester
NCT06274515 on ClinicalTrials.gov ↗
Recruiting Phase 1
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC), Synovial Sarcomas, Head and Neck Cancer
Zelluna Immunotherapy AS · started 2026-05-11
London · Manchester
NCT07613723 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
Alcohol Use Disorder
Eli Lilly and Company · started 2025-10-15
Blackpool · Chester · Eastbourne · Edinburgh · Glasgow
NCT07219966 on ClinicalTrials.gov ↗
Active Phase 3
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Prostate Cancer
Pfizer · started 2021-05-12
Exeter · Maidstone · Preston · Edinburgh · Glasgow
NCT04821622 on ClinicalTrials.gov ↗
Recruiting Phase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
Pfizer · started 2025-08-20
London · Manchester
NCT07090499 on ClinicalTrials.gov ↗
Recruiting Phase 3
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
ADARx Pharmaceuticals, Inc. · started 2026-04-02
Cambridge · Cardiff · London · Southampton
NCT07428499 on ClinicalTrials.gov ↗
Active Phase 1/Phase 2
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Novartis Pharmaceuticals · started 2025-04-22
Sheffield · London
NCT06704269 on ClinicalTrials.gov ↗
Starting soon
SNIP follow-on Case Series Using v3 Device
Ankyloglossia
Europa Life Sciences Limited · started 2026-10-01
Royal Tunbridge Wells
NCT07796165 on ClinicalTrials.gov ↗
Recruiting
Patient Retrospective Outcomes (PRO)
Chronic Pain
Boston Scientific Corporation · started 2012-04-03
Basildon · Bristol · Exeter · Leeds · London
NCT01550575 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Diabetes Mellitus, Type 1
Eli Lilly and Company · started 2026-01-12
Birmingham · Cambridge · Cardiff · Glasgow · London
NCT07222137 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study of Brenipatide in Participants With Opioid Use Disorder
Opioid Use Disorder
Eli Lilly and Company · started 2026-02-13
Chertsey · Doncaster · Eastbourne · Glasgow · London
NCT07420283 on ClinicalTrials.gov ↗
Active Phase 1/Phase 2
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
AbbVie · started 2018-01-02
Oxford
NCT03386513 on ClinicalTrials.gov ↗
Recruiting Phase 3
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
Relapsed or Refractory Large B-cell Lymphoma
Kite, A Gilead Company · started 2026-05-22
Newcastle upon Tyne
NCT07479797 on ClinicalTrials.gov ↗
Recruiting Phase 2
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
Breast Cancer
Hoffmann-La Roche · started 2026-02-18
Blackpool · Harlow · Northwood, Middlesex · Oxford
NCT07368998 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Solid Tumors
ORIC Pharmaceuticals · started 2022-03-10
Manchester
NCT05315700 on ClinicalTrials.gov ↗
Active Phase 3
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
Chronic Migraine
Ipsen · started 2023-10-12
Brighton · Brixton
NCT06047444 on ClinicalTrials.gov ↗
Active
A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
Spasticity as Sequela of Stroke
Ipsen · started 2023-11-01
Leicester · Liverpool · London · Middlesbrough · Nottingham
NCT06055725 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
Advanced Prostate Cancer, Metastatic Prostate Cancer
Genentech, Inc. · started 2026-04-29
Sutton
NCT07567846 on ClinicalTrials.gov ↗
Active Phase 3
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
Non-alcoholic Steatohepatitis
Novo Nordisk A/S · started 2021-04-01
Belfast · Birmingham · Coventry · Derby · Dundee
NCT04822181 on ClinicalTrials.gov ↗
Recruiting Phase 3
Pivotal Study of N-acetyl-L-leucine for CACNA1A
CACNA1A, Spinocerebellar Ataxia Type 6, Episodic Ataxia Type 2, Familial Hemiplegic Migraine-1
IntraBio Inc · started 2026-08-17
Oxford
NCT07221292 on ClinicalTrials.gov ↗
Recruiting Phase 3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals · started 2026-05-11
Dorchester · London · Preston · Harrow · Rochdale
NCT07517263 on ClinicalTrials.gov ↗
Active Phase 3
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Menstrual Migraine (MM)
AbbVie · started 2025-02-10
Poole · Brighton · London · Thetford · Oxford
NCT06806293 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Diabetes Mellitus, Type 1
Eli Lilly and Company · started 2026-02-05
Aberdeen · Birmingham · Bristol · Cambridge · Cardiff
NCT07222332 on ClinicalTrials.gov ↗
Recruiting
Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU)
Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases
Edwards Lifesciences · started 2024-10-01
Oxford
NCT06569602 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
UCB Biopharma SRL · started 2024-11-21
Bath · Belfast · Leeds · London · Newcastle upon Tyne
NCT06617325 on ClinicalTrials.gov ↗
Recruiting
Clinical Investigation of the Performance of Epinamel for Dental White Spot Lesions
White Spot Lesions [Initial Caries] on Smooth Surface of Tooth
Mintech Bio Ltd · started 2026-07-06
London
NCT07730359 on ClinicalTrials.gov ↗
Recruiting Phase 3
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Non-small Cell Lung Cancer (NSCLC)
AstraZeneca · started 2025-10-31
Huddersfield · London · Maidstone · Norwich · Stoke-on-Trent
NCT07291037 on ClinicalTrials.gov ↗
Recruiting Phase 4
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Eli Lilly and Company · started 2026-03-09
Hull · Leeds · Newmarket
NCT07218341 on ClinicalTrials.gov ↗
Active Phase 2
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
Diabetic Retinopathy
Boehringer Ingelheim · started 2024-05-15
Colchester · Liverpool · London · Newcastle upon Tyne
NCT06321302 on ClinicalTrials.gov ↗
Active Phase 3
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
Obesity and Overweight
Pfizer · started 2025-12-19
Sandbach · Hendon · Glasgow · Bellshill · Birmingham
NCT07311850 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Neoplasms
Celgene · started 2018-07-19
Leeds · London · Manchester Withington · Shirley Southampton
NCT03435796 on ClinicalTrials.gov ↗
Recruiting Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company · started 2025-09-02
Belfast · Birmingham · Blackpool · Bodelwyddan · Bradford-on-Avon
NCT07157774 on ClinicalTrials.gov ↗
Active Phase 2
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
ANCA Associated Vasculitis (AAV)
Novartis Pharmaceuticals · started 2025-03-13
Cambridge · Glasgow · London · Manchester
NCT06868290 on ClinicalTrials.gov ↗
Active
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular · started 2021-10-20
Oxford
NCT05198674 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Small-cell Lung Cancer
Zai Lab (Shanghai) Co., Ltd. · started 2025-11-30
Cambridge · London · Chelsea · Sutton · Stoke-on-Trent
NCT07218146 on ClinicalTrials.gov ↗
Recruiting Phase 1
Human Mass Balance Study of [14C] Ontunisertib in Healthy Volunteers
Fibrostenotic Crohn's Disease
Agomab Spain S.L.U. · started 2026-09-09
Nottingham
NCT07672574 on ClinicalTrials.gov ↗
Active Phase 1/Phase 2
First-in-Human Study of ICT01 in Patients With Advanced Cancer
Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer
ImCheck Therapeutics, an Ipsen company · started 2020-03-05
Glasgow · London
NCT04243499 on ClinicalTrials.gov ↗
By invitation
Registry of Patients With Hypophosphatasia
Hypophosphatasia (HPP)
Alexion Pharmaceuticals, Inc. · started 2015-01-20
Bristol · London · Leicester · Stanmore · Oxford
NCT02306720 on ClinicalTrials.gov ↗
Active Phase 2/Phase 3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Biogen · started 2022-09-13
London · Manchester · Birmingham · Leeds
NCT05531565 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
Pfizer · started 2025-09-29
London · Manchester
NCT07144280 on ClinicalTrials.gov ↗
By invitation Phase 3
An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)
Biogen · started 2022-06-10
London · Doncaster · Cannock
NCT05352919 on ClinicalTrials.gov ↗
Active Phase 2
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
Parkinsons Disease
Hoffmann-La Roche · started 2021-05-05
Dundee · London · Newcastle · Oxford · Peterborough
NCT04777331 on ClinicalTrials.gov ↗
Recruiting Phase 2
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
PIK3CA-related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals · started 2025-10-09
Liverpool · London
NCT06997588 on ClinicalTrials.gov ↗
Active Phase 3
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
Generalized Anxiety Disorder
Definium Therapeutics US, Inc. · started 2025-01-29
Glasgow · Gosforth · London · Manchester · Sheffield
NCT06809595 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Myasthenia Gravis, Generalized
Vertex Pharmaceuticals Incorporated · started 2026-05-13
Birmingham · London · Salford
NCT07501702 on ClinicalTrials.gov ↗
Recruiting
TrueLok Elevate PMCF Study
Wound of Skin, Ulcers, Soft Tissue Defect
Orthofix s.r.l. · started 2025-11-24
Hull · Newcastle upon Tyne
NCT07079774 on ClinicalTrials.gov ↗
Recruiting Phase 3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
AbbVie · started 2025-11-05
Gloucester · London · Liverpool · Bristol · Sunderland
NCT07007065 on ClinicalTrials.gov ↗
Active Phase 3
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
Overweight, Obesity, Type 2 Diabetes
Novo Nordisk A/S · started 2025-11-05
Liskeard · Newquay · Torquay · Bushey · London
NCT07220759 on ClinicalTrials.gov ↗
Recruiting Phase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Ulcerative Colitis, Obesity or Overweight
Eli Lilly and Company · started 2025-06-26
Bristol · Dundee · Exeter · London
NCT06937086 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
Turning Point Therapeutics, Inc. · started 2020-03-12
Liverpool · Birmingham · Cardiff · Glasgow · London
NCT04094610 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Non Small Cell Lung Carcinoma
AbbVie · started 2025-03-06
Leicester · Cardiff
NCT06772623 on ClinicalTrials.gov ↗
Recruiting Phase 1
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
Huntington's Disease
Sarepta Therapeutics, Inc. · started 2026-05-12
Cardiff
NCT07536061 on ClinicalTrials.gov ↗
Recruiting Phase 1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company · started 2024-07-01
London · Manchester
NCT06465069 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
Ulcerative Colitis
AbbVie · started 2025-07-28
Cambridge · Sheffield · Liverpool
NCT07071519 on ClinicalTrials.gov ↗
Recruiting Phase 3
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
Growth Hormone Deficiency (GHD)
Lumos Pharma · started 2026-05-20
Liverpool · London · Sheffield
NCT06948214 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics · started 2026-02-02
Birmingham · Edgbaston · Trumpington · Exeter · Oxford
NCT06968845 on ClinicalTrials.gov ↗
Active Phase 2
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
Head and Neck Squamous Cell Carcinoma
Gilead Sciences · started 2025-02-18
London
NCT06727565 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Merck Sharp & Dohme LLC · started 2025-04-09
Cambridge · Edinburgh · Preston · London · Sutton
NCT06824467 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer
Hoffmann-La Roche · started 2026-03-11
Sutton · Cardiff
NCT07287150 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Heart Failure
Boehringer Ingelheim · started 2025-05-20
Bristol · Clydebank · Exeter · Halifax · Harrow
NCT06935370 on ClinicalTrials.gov ↗
Recruiting Phase 2
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)
ADARx Pharmaceuticals, Inc. · started 2025-08-28
Leicester · Newcastle upon Tyne
NCT06989359 on ClinicalTrials.gov ↗
Active Phase 1
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
Solid Tumors
ModernaTX, Inc. · started 2017-08-14
Dundee · Sutton · London
NCT03313778 on ClinicalTrials.gov ↗
Active Phase 3
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Melanoma
Pfizer · started 2021-01-15
London · Swansea
NCT04657991 on ClinicalTrials.gov ↗
Recruiting Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC · started 2024-06-24
Bristol · Truro · London · Edinburgh · Leeds
NCT06393374 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
Merck Sharp & Dohme LLC · started 2024-08-16
Birmingham · Newcastle upon Tyne · London · Sutton · Cardiff
NCT06395103 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Breast Neoplasms
Merck Sharp & Dohme LLC · started 2024-04-14
Londonderry · Truro · London · Blackpool · Nottingham
NCT06312176 on ClinicalTrials.gov ↗
Recruiting Phase 3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Non-small Cell Lung Cancer
Boehringer Ingelheim · started 2026-01-16
Cardiff · Edinburgh · London · Manchester · Sutton
NCT07195695 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Bladder Cancer
Merck Sharp & Dohme LLC · started 2026-04-23
Cambridge · London
NCT07419295 on ClinicalTrials.gov ↗
Recruiting Phase 3
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease
Dyne Therapeutics · started 2026-05-14
London · Salford
NCT07486934 on ClinicalTrials.gov ↗
Recruiting Phase 2
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
AbbVie · started 2026-01-23
Cambridge · Edinburgh · London · Southampton · Norwich
NCT07230288 on ClinicalTrials.gov ↗
Active Phase 2
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Alnylam Pharmaceuticals · started 2024-05-17
London
NCT06393712 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
Merck Sharp & Dohme LLC · started 2024-06-20
London · Coventry
NCT06428409 on ClinicalTrials.gov ↗
Recruiting Phase 2
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc. · started 2025-11-10
Liverpool · Dorchester · Wolverhampton · London · Sunderland
NCT06990269 on ClinicalTrials.gov ↗
Recruiting
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb · started 2025-10-08
Oxford · Bath · Wolverhampton · London
NCT07175285 on ClinicalTrials.gov ↗
Recruiting Phase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer
Relay Therapeutics, Inc. · started 2025-08-26
Bath · Cardiff · London · Manchester · Swindon
NCT06982521 on ClinicalTrials.gov ↗
Recruiting Phase 1
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
Context Therapeutics Inc. · started 2024-07-10
London
NCT06515613 on ClinicalTrials.gov ↗
Recruiting Phase 4
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
Muscular Atrophy, Spinal
Hoffmann-La Roche · started 2024-05-30
London
NCT05861986 on ClinicalTrials.gov ↗
Recruiting Phase 3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Bronchiectasis
Boehringer Ingelheim · started 2025-06-09
Belfast · Birmingham · Blackpool · Bradford · Bristol
NCT06872892 on ClinicalTrials.gov ↗
Active
First in Human Clinical Investigation of the FIRE1 System in Heart Failure Patients (FUTURE-HF)
Heart Failure
Foundry Innovation & Research 1, Limited (FIRE1) · started 2019-11-22
Bournemouth · Glasgow · Leicester · London · Portsmouth
NCT04203576 on ClinicalTrials.gov ↗
Recruiting Phase 3
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
Active Juvenile Psoriatic Arthritis
Amgen · started 2022-03-17
Birmingham · Liverpool · Nottingham · Oxford
NCT04804553 on ClinicalTrials.gov ↗
Starting soon Phase 1
Phase 1 PK Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
COPD (Chronic Obstructive Pulmonary Disease)
AeroRx Therapeutics Inc. · started 2026-09
Manchester
NCT07802730 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Lymphoma
Hoffmann-La Roche · started 2023-10-22
Glasgow · Lincoln · London · Manchester · Oxford
NCT06084936 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC · started 2026-04-09
Edinburgh · Leicester · Withington
NCT07489495 on ClinicalTrials.gov ↗
Starting soon Phase 1/Phase 2
A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)
Mucopolysaccharidosis IIIB
JCR Pharmaceuticals Co., Ltd. · started 2026-09-04
London
NCT07640984 on ClinicalTrials.gov ↗
Recruiting Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Boehringer Ingelheim · started 2025-07-22
Birmingham · Blackburn · Bournemouth · Bradford · Bristol
NCT07064473 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Parkinson's Disease
Hoffmann-La Roche · started 2025-11-24
Dundee · Exeter · London · Newcastle · Oxford
NCT07174310 on ClinicalTrials.gov ↗
Active
A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Paroxysmal Nocturnal Hemoglobinuria
Swedish Orphan Biovitrum · started 2023-06-26
London
NCT05776472 on ClinicalTrials.gov ↗
Recruiting Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Prostate Cancer Metastatic
Merck Sharp & Dohme LLC · started 2023-12-31
Cambridge · Truro · Glasgow · London · Manchester
NCT06136624 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Chronic Migraine
AbbVie · started 2025-02-13
London · Gillingham · Aberdeen · Stockport
NCT06810505 on ClinicalTrials.gov ↗
Recruiting Phase 2
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
Advanced Breast Cancer
AstraZeneca · started 2026-05-06
Cambridge · London · Manchester
NCT07427394 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc. · started 2025-08-19
London
NCT07005154 on ClinicalTrials.gov ↗
Recruiting Phase 2
Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma
Glioblastoma
CRISM Therapeutics LTD · started 2026-08-20
Birmingham
NCT07356973 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
89bio, Inc. · started 2024-05-24
Aberdeen · Bristol · Leeds · London · Oxford
NCT06419374 on ClinicalTrials.gov ↗
Recruiting Phase 3
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
AstraZeneca · started 2025-03-27
Bath · Cambridge · Leeds · London · Manchester
NCT06989112 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)
Alpha-1 Antitrypsin Deficiency (AATD)
Tessera Therapeutics, Inc. · started 2026-04-21
London · Nottingham
NCT07227207 on ClinicalTrials.gov ↗
Active Phase 3
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Breast Cancer
Hoffmann-La Roche · started 2021-05-04
Blackpool · Brighton · Cambridge · Cheltenham · London
NCT04873362 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Merck Sharp & Dohme LLC · started 2026-01-19
Edinburgh · Withington
NCT07216703 on ClinicalTrials.gov ↗
Starting soon Phase 3
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
Interstitial Lung Diseases
Boehringer Ingelheim · started 2026-09-14
Birmingham · Exeter · Leeds · Leicester · London
NCT07540988 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Elevar Therapeutics · started 2026-06-04
London · Manchester
NCT07359820 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca · started 2025-03-18
Bradford · Brighton · Cottingham · Glasgow · Halifax
NCT06883305 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
HER2-positive Breast Cancer
Hoffmann-La Roche · started 2026-05-21
Leicester · London · Manchester · Montacute
NCT07413939 on ClinicalTrials.gov ↗
Recruiting Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Non-small Cell Lung Cancer, NSCLC
Merck Sharp & Dohme LLC · started 2024-06-10
Londonderry · Torquay · London · Nottingham
NCT06422143 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Ovarian Neoplasms, Ovarian Cancer
Merck Sharp & Dohme LLC · started 2026-02-16
Cambridge · Leicester · London · Manchester
NCT07318558 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
Macular Edema
Boehringer Ingelheim · started 2025-06-05
Camberley · Gloucester · Harrow · Liverpool · London
NCT06962839 on ClinicalTrials.gov ↗
Recruiting Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Amgen · started 2025-07-25
Birmingham · Blackpool · Bristol · Cambridge · Chester
NCT07037433 on ClinicalTrials.gov ↗
Recruiting Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Hepatocellular Carcinoma
AstraZeneca · started 2025-05-06
Cambridge · Leeds · London · Manchester
NCT06921785 on ClinicalTrials.gov ↗
Recruiting Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid Tumors, Hematologic Malignancies
Merck Sharp & Dohme LLC · started 2018-08-21
Aberdeen · Cambridge · Edinburgh · Manchester · Sheffield
NCT03486873 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Lymphoma, Large B-Cell, Diffuse
Merck Sharp & Dohme LLC · started 2025-04-11
Bristol · Aylesbury · Exeter · Plymouth · Middlesbrough
NCT06890884 on ClinicalTrials.gov ↗
Starting soon
Acceptability and Tolerance Market Research of a Slow Release, Phenylalanine-free Protein Substitute for the Dietary Management of Phenylketonuria
Phenylketonuria (PKU) and Hyperphenylalaninemia, Brain Diseases, Metabolic, Inborn, Brain Disorder, Metabolic, Brain Diseases
metaX Institut fuer Diatetik GmbH · started 2026-10-01
Birmingham
NCT07802366 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Prostatic Neoplasms, Castration-Resistant
Merck Sharp & Dohme LLC · started 2024-05-20
Cambridge · Glasgow · Preston · London · Birmingham
NCT06353386 on ClinicalTrials.gov ↗
Recruiting Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
Merck Sharp & Dohme LLC · started 2021-08-12
Cambridge · London · Glasgow
NCT04924075 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
Obesity, Overweight
Boehringer Ingelheim · started 2026-06-30
Blackpool · Guisborough · High Wycombe · Leicester · Middlesbrough
NCT07662122 on ClinicalTrials.gov ↗
Recruiting Phase 3
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
Obesity, Overweight
Kailera · started 2025-12-18
Soham · Torpoint · Hull · Stevenage · Leicester
NCT07284875 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Gaucher Disease Gene Therapy Trial With FLT201
Gaucher Disease Type 1
Spur Therapeutics · started 2026-04-07
Birmingham · Salford · London · Cambridge
NCT07223944 on ClinicalTrials.gov ↗
Recruiting Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Metabolic Dysfunction Associated Steatohepatitis
Boehringer Ingelheim · started 2024-11-12
Aberdeen · Bristol · Camberley · Derby · Edgbaston, Birmingham
NCT06632457 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Prostate Cancer, Prostatic Neoplasms
Merck Sharp & Dohme LLC · started 2025-05-13
Cambridge · London · Exeter · Birmingham · Northwood
NCT06925737 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Lupus Nephritis
Hoffmann-La Roche · started 2022-05-12
Glasgow · Liverpool · London
NCT05039619 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Episodic Migraine
AbbVie · started 2023-05-01
London · Gillingham · Aberdeen · Stockport
NCT05711394 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
DLBCL, Diffuse Large B-Cell Lymphoma
Merck Sharp & Dohme LLC · started 2022-01-14
Aberdeen · Truro · London-Camden
NCT05139017 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
Severe Asthma
Generate Biomedicines · started 2026-01-20
High Wycombe · Bristol · London · Romford · Rotherham
NCT07359846 on ClinicalTrials.gov ↗
Starting soon
A Clinical Study to Assess the Efficacy of a Calcium Sodium Phosphosilicate Toothpaste for the Relief of Dentine Hypersensitivity
Dentin Sensitivity
HALEON · started 2026-09
Bristol
NCT07802886 on ClinicalTrials.gov ↗
Recruiting Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC · started 2023-12-15
London · Portsmouth · Canterbury · Central Middlesbrough
NCT06170788 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca · started 2023-12-14
Aberdeen · Cambridge · Hampshire · Leeds · London
NCT06129864 on ClinicalTrials.gov ↗
Active Phase 3
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
Non-Small Cell Lung Cancer
AstraZeneca · started 2019-07-02
Cambridge · Leicester · Liverpool · Maidstone · Manchester
NCT04035486 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc. · started 2024-03-13
High Wycombe · Bristol · Glasgow · Hull · London
NCT06318169 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC · started 2025-03-16
Truro · London · Nottingham · Taunton · Birmingham
NCT06841354 on ClinicalTrials.gov ↗
Active Phase 3
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis
Hoffmann-La Roche · started 2021-03-24
Salford
NCT04586023 on ClinicalTrials.gov ↗
Recruiting Phase 3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Metastatic Colorectal Cancer
Amgen · started 2024-07-17
Birmingham · Glasgow · London · Maidstone · Northwood
NCT06252649 on ClinicalTrials.gov ↗
Active Phase 1
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Hoffmann-La Roche · started 2023-12-18
London
NCT05835986 on ClinicalTrials.gov ↗
Recruiting Phase 3
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Von Hippel-Lindau Disease, Malignant Neoplasms
Merck Sharp & Dohme LLC · started 2026-03-23
Glasgow · London · Manchester
NCT07405164 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies
Solid Malignancies
Carrick Therapeutics Limited · started 2024-08-16
Manchester · Oxford · Sutton
NCT06600789 on ClinicalTrials.gov ↗
Active Phase 3
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
Multiple Sclerosis, Primary Progressive
Hoffmann-La Roche · started 2020-10-26
Glasgow · London · Nottingham · Swansea
NCT04544449 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Systemic Sclerosis
Boehringer Ingelheim · started 2026-07-27
Bristol · Leeds · London · Salford
NCT07497087 on ClinicalTrials.gov ↗
Recruiting
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
Geographic Atrophy Secondary to Age-related Macular Degeneration
Complement Therapeutics · started 2025-07-30
Gloucester · London · Southampton · Sunderland · Belfast
NCT07144137 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC · started 2025-06-30
London · Dundee · Huddersfield · Colchester · Orpington
NCT06966700 on ClinicalTrials.gov ↗
Recruiting Phase 3
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Obesity With Diabetes, Overweight With Diabetes
Kailera · started 2026-01-12
Truro · Plymouth · Bournemouth · Hull · Glasgow
NCT07284901 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Breast Cancer
Hoffmann-La Roche · started 2025-04-09
Blackpool · Colchester, Essex · Edinburgh · Harlow · London
NCT06790693 on ClinicalTrials.gov ↗
Active Phase 3
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
Wet Age Related Macular Degeneration, wAMD
EyePoint Pharmaceuticals, Inc. · started 2024-11-27
London
NCT06683742 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
Merck Sharp & Dohme LLC · started 2026-05-03
Plymouth · Manchester
NCT07519772 on ClinicalTrials.gov ↗
Recruiting Phase 1
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
Muscular Atrophy, Spinal
Biogen · started 2025-01-16
Sheffield
NCT06555419 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
BioNTech SE · started 2026-04-22
Cambridge · London · Sutton
NCT07365995 on ClinicalTrials.gov ↗
Active Phase 1
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
Head and Neck Squamous Cell Carcinoma
Boehringer Ingelheim · started 2025-05-14
London · Sutton
NCT06806852 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Celgene · started 2022-09-20
Cambridge · Truro · Airdrie · London · Leicester
NCT05519085 on ClinicalTrials.gov ↗
Recruiting Phase 3
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Advanced Breast Cancer
AstraZeneca · started 2024-08-01
Cambridge · Guildford · London · Manchester · Oxford
NCT06380751 on ClinicalTrials.gov ↗
Active Phase 3
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Ductal Adenocarcinoma
Arcus Biosciences, Inc. · started 2024-12-13
Birmingham · Cottingham · London · Manchester
NCT06608927 on ClinicalTrials.gov ↗
Active Phase 1/Phase 2
Gene Transfer Study in Patients With Late Onset Pompe Disease
Pompe Disease (Late-onset)
Astellas Gene Therapies · started 2020-10-27
Newcastle upon Tyne
NCT04174105 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Cancer
Hoffmann-La Roche · started 2023-06-01
Leicester · Surrey
NCT05862285 on ClinicalTrials.gov ↗
Active
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
Cardiomyopathy
Tenaya Therapeutics · started 2021-11-01
Glasgow · London
NCT05112237 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Renal Cell Carcinoma
Merck Sharp & Dohme LLC · started 2025-07-20
Edinburgh · Glasgow · London · Cardiff · Manchester
NCT07049926 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc. · started 2025-12-11
Cardiff · London · Manchester · Sheffield
NCT07144163 on ClinicalTrials.gov ↗
Recruiting Phase 2
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
Solid Tumours
Boehringer Ingelheim · started 2024-10-11
Dundee · London · Manchester
NCT06581432 on ClinicalTrials.gov ↗
No trials match your search.

Browse by city

London · 112 Manchester · 38 Cambridge · 28 Glasgow · 27 Birmingham · 27 Oxford · 23 Leicester · 20 Bristol · 20 Leeds · 16 Cardiff · 16 Liverpool · 15 Edinburgh · 13 Sheffield · 13 Sutton · 13 Newcastle upon Tyne · 12 Exeter · 12

Browse by condition

Obesity · 5 Breast Cancer · 5 Solid Tumors · 4 Overweight · 4 Non-small Cell Lung Cancer · 3 Ovarian Cancer · 3 Prostate Cancer · 3 Cardiovascular Diseases · 3 Bladder Cancer · 2 Diabetes Mellitus, Type 1 · 2 Chronic Migraine · 2 Systemic Lupus Erythematosus · 2 Non-small Cell Lung Cancer (NSCLC) · 2 Hypertension · 2 Systemic Lupus Erythematosus (SLE) · 2 Ulcerative Colitis · 2
Cite this page

Priya Life Science (2026). Clinical Trials in the UK Tracker. Available at: https://priyalifescience.com/clinical-trials-uk (Accessed: 6 September 2026).

Embed this data ↗

Source: ClinicalTrials.gov, U.S. National Library of Medicine — industry-sponsored studies in a recruiting status with at least one UK site, most recently updated first, refreshed daily. This is a curated slice of the registry, not every UK trial; UK studies may also be registered on ISRCTN. Listing here is informational and not medical advice; eligibility is determined by each study team. Patients should discuss participation with their clinician. Compare pay for the teams running these studies in our UK Pharma Salary Guide, or see our Ireland, EU and USA trackers.